PT  - JOURNAL ARTICLE
AU  - Mark J. Clair
AU  - Mary K. King
AU  - Aron T. Goldberg
AU  - Jennifer W. Hendrick
AU  - Riccardo Nisato
AU  - David M. Gay
AU  - Allison E. Morrison
AU  - James H. McElmurray III
AU  - R. Stephen Krombach
AU  - Brian R. Bond
AU  - Catherine Cazaubon
AU  - Dino Nisato
AU  - Francis G. Spinale
TI  - Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure
DP  - 2000 Jun 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 852--860
VI  - 293
IP  - 3
4099  - http://jpet.aspetjournals.org/content/293/3/852.short
4100  - http://jpet.aspetjournals.org/content/293/3/852.full
SO  - J Pharmacol Exp Ther2000 Jun 01; 293
AB  - With developing congestive heart failure (CHF), activation of the vasopressin V1a and angiotensin II type 1 (AT1) receptors can occur. In the present study, we examined the direct effects of V1a receptor blockade (V1a block), selective AT1 receptor blockade (AT1 block), and dual V1a/AT1receptor blockade (dual block) with respect to left ventricular (LV) function and contractility during the progression of CHF. LV and myocyte functions were examined in pigs with pacing CHF (rapid pacing, 240 beats/min, 3 weeks, n = 10), pacing CHF with concomitant V1a block (SR49059, 60 mg/kg,n = 8), pacing CHF with concomitant AT1block (irbesartan, 30 mg/kg, n = 7), or pacing CHF with dual block (n = 7). LV end-diastolic dimension and peak wall stress were reduced in all receptor blockade groups compared with CHF values. However, LV fractional shortening was increased only in the dual block group compared with CHF values (29 ± 3 versus 21 ± 2, P < .05). Basal LV myocyte percent shortening increased in the dual block group compared with CHF values (3.44 ± 0.23 versus 2.88 ± 0.11,P < .05). Although V1a or AT1 block reduced LV loading conditions, only dual block resulted in improved LV and myocyte shortening. The American Society for Pharmacology and Experimental Therapeutics